Dyne’s DMD Therapy Wins Priority Review
The FDA accepted Dyne Therapeutics’ biologics license application for zeleciment rostudirsen and granted Priority Review for Duchenne muscular dystrophy amenable to exon 51 skipping. The milestone places Dyne’s antibody-oligonucleotide conjugate at the center of…
